FTC Sues WPATH Over Transgender Youth Treatment Guidelines, Citing Deceptive Evidence Standards

The Federal Trade Commission, joined by the attorneys general of Alaska, Iowa, Nebraska, and Texas, filed a complaint in federal court in Texas against the World Professional Association for Transgender Health, alleging the organization publicly described its medical guidelines for transgender minors as evidence-based while its own leaders privately acknowledged the underlying research was limited and uncertain. The lawsuit targets WPATH's Standards of Care — widely cited guidelines that have shaped treatment protocols, insurance coverage decisions, and professional guidance across the United States. FTC Chairman Andrew Ferguson called the case a consumer-protection matter, stating that families must have complete and truthful information when deciding whether to purchase medical services for their children.

What the Complaint Alleges

At the center of the federal complaint are internal communications that regulators say contradict WPATH's public-facing claims. A 2023 strategy memo from Dr. Eli Coleman, lead author of the Standards of Care 8th edition, acknowledged that "all of us are painfully aware that there are many gaps in research to back up our recommendations." Separately, Dr. Amy Tishelman, lead author of the WPATH chapter on children, said in an NPR interview that there was no established "research basis" for determining the best assessments or treatments for transgender youth. Regulators also allege WPATH removed age minimums from its 2022 Standards of Care — including for breast removal surgeries — without scientific justification, citing internal discussions in which some leaders struggled to identify evidence-based reasons for the change.

Conflict-of-Interest Allegations and Suicide-Risk Claims

The complaint further alleges that many clinicians and surgeons who helped draft WPATH's guidelines had financial and professional interests tied to the treatments they were recommending. Kurt Miceli, chief medical officer for Do No Harm, a medical ethics advocacy organization, said the organization stacked its drafting process with individuals who had a financial stake in promoting pediatric medical transition. Regulators allege WPATH promoted transition procedures as "lifesaving" despite insufficient evidence that the interventions reduce suicide risk, and that some parents were told to consider whether they would "rather have a live daughter or a dead son" when weighing treatment options — a claim Miceli said is unsupported by any evidence.

WPATH's Response and Broader Implications

WPATH rejected the allegations Wednesday, calling the lawsuit politically motivated and legally flawed. The organization said it has spent more than 50 years developing guidelines grounded in scientific standards, expert consensus, and patient-centered values, and characterized the action as another instance of the Trump administration using federal agency authority to interfere with the patient-physician relationship. The stakes extend well beyond WPATH's membership: it is a co-sponsoring organization of the Endocrine Society's clinical practice guideline on gender dysphoria, and the American Academy of Child and Adolescent Psychiatry identifies both as the most widely used clinical guidelines for providers treating youth with gender dysphoria. Miceli called on the American Medical Association, the Endocrine Society, the American Academy of Pediatrics, and the American Psychiatric Association to conduct their own reviews of the evidence underlying their reliance on WPATH guidance.